Latigo Biotherapeutics has submitted its initial public offering (IPO) registration and plans to trade on the Nasdaq Global Select Market under the ticker symbol LTGO. The firm’s oral small molecule Nav1.8 inhibitor LTG-001 has already completed a Phase II clinical trial (NCT06774625). Topline results are anticipated in the second half of 2027. The firm said in the filing that it has initiated a Phase II proof-of-concept study, with readouts also anticipated in the second half of 2027. Latigo has accumulated roughly $321.5 million in total funding since its 2018 founding.